DOI QR코드

DOI QR Code

Research on the Relationship Between Serum Levels of Inflammatory Cytokines and Non-small Cell Lung Cancer

  • Song, Xiao-Yun (Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University) ;
  • Zhou, Shi-Jie (Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University) ;
  • Xiao, Ning (Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University) ;
  • Li, Yun-Song (Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University) ;
  • Zhen, De-Zhi (Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University) ;
  • Su, Chong-Yu (Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University) ;
  • Liu, Zhi-Dong (Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University)
  • Published : 2013.08.30

Abstract

Aims: This study was conducted to evaluate the levels of TNF-${\alpha}$, IL-6, IL-8 and VEGF in serum of patients with non- small cell lung cancer, for assessing their possible diagnostic and prognostic roles. Methods: We enrolled 48 patients newly diagnosed with non-small cell lung cancer and 40 healthy controls. TNF- ${\alpha}$, IL-6 and IL-8 levels were measured in the serum of all the subjects with specific radioimmunoassay kits, while EGF was analyzed by sandwich enzyme immunoassay techniques. Results: A statistically significant difference was observed between lung cancer patients and the control group regarding the values of TNF-${\alpha}$, IL-6, IL-8 and VEGF in serum. Moreover, TNF-${\alpha}$, IL-8 and VEGF levels were higher in patients with advanced stages compared to early stages. In addition, higher serum levels of TNF-${\alpha}$, IL-6, IL-8 and VEGF were found in smokers than in non-smokers, both in patients and controls. Conclusion: Serum levels of TNF-${\alpha}$, IL-6, IL-8 and VEGF were all elevated in lung cancer patients, suggesting that inflammatory cytokines could be jointly used as a screening tool. Though TNF-${\alpha}$, IL-8 and VEGF levels were related to advanced disease, long-term survival studies of NSCLC patients should be performed to confirm whether they can act as biomarkers of advanced disease. In addition, smoking would be an important contributor to the processes of inflammation and lung cancer.

Keywords

TNF-${\alpha}$;IL-6;IL-8;VEGF;serum values;non-small cell lung cancer

References

  1. Beasley MB, Brambilla E, Travis WD (2005). The 2004 World Health Organization classification of lung tumors. Semin Roentgenol, 40, 90-7. https://doi.org/10.1053/j.ro.2005.01.001
  2. Bodelon C, Polley MY, Kemp TJ, et al (2013). Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer. Ann Oncol, 24, 2073-9. https://doi.org/10.1093/annonc/mdt175
  3. Boldrini L, Calcinai A, Samaritani E, et al (2000). Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer, 83, 480-6. https://doi.org/10.1054/bjoc.2000.1345
  4. Cheng D, Kong H, Li Y (2013). Prognostic values of VEGF and IL-8 in malignant pleural effusion in patients with lung cancer. Biomarkers, 18, 386-90. https://doi.org/10.3109/1354750X.2013.797499
  5. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7. https://doi.org/10.1038/nature01322
  6. Dalaveris E, Kerenidi T, Katsabeki-Katsafli A, et al (2009). VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. Lung Cancer, 64, 219-25. https://doi.org/10.1016/j.lungcan.2008.08.015
  7. Ferlay J, Autier P, Boniol M, et al (2007). Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol, 18, 581-92.
  8. Grivennikov SI, Greten FR, Karin M (2010). Immunity, inflammation, and cancer. Cell, 140, 883-99. https://doi.org/10.1016/j.cell.2010.01.025
  9. Hashimoto K, Ikeda Y, Korenaga D, et al (2005). The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer, 103, 1856-64. https://doi.org/10.1002/cncr.20976
  10. Il’yasova D, Colbert LH, Harris TB, et al (2005). Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev, 14, 2413-8. https://doi.org/10.1158/1055-9965.EPI-05-0316
  11. Lagiou P, Trichopoulos D (2011). Inflammatory biomarkers and risk of lung cancer. J Natl Cancer Inst, 103, 1073-5. https://doi.org/10.1093/jnci/djr220
  12. Matsuyama W, Hashiguchi T, Mizoguchi A, et al (2000). Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest, 118, 948-51. https://doi.org/10.1378/chest.118.4.948
  13. Millar HJ, Nemeth JA, McCabe FL, et al (2008). Circulating human interleukin-8 as an indicator of cancer progression in a nude rat orthotopic human non-small cell lung carcinoma model. Cancer Epidemiol Biomarkers Prev, 17, 2180-7. https://doi.org/10.1158/1055-9965.EPI-07-2915
  14. Peto R, Darby S, Deo H, et al (2000). Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ, 321, 323-9. https://doi.org/10.1136/bmj.321.7257.323
  15. Pine SR, Mechanic LE, Enewold L, et al (2011). Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst, 103, 1112-22. https://doi.org/10.1093/jnci/djr216
  16. Saito A, Suzuki HI, Horie M, et al (2013). An integrated expression profiling reveals target genes of TGF-beta and TNF-alpha possibly mediated by microRNAs in lung cancer cells. PLoS One, 8, e56587. https://doi.org/10.1371/journal.pone.0056587
  17. Scott HR, McMillan DC, Forrest LM, et al (2002). The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer, 87, 264-7. https://doi.org/10.1038/sj.bjc.6600466
  18. Siemes C, Visser LE, Coebergh JW, et al (2006). C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol, 24, 5216-22. https://doi.org/10.1200/JCO.2006.07.1381
  19. Takigawa N, Segawa Y, Fujimoto N, et al (1998). Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res, 18, 1251-4.
  20. Tas F, Duranyildiz D, Argon A, et al (2005). Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol, 22, 353-8. https://doi.org/10.1385/MO:22:4:353
  21. Tas F, Duranyildiz D, Oguz H, et al (2006). Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest, 24, 576-80. https://doi.org/10.1080/07357900600894781
  22. Volm M, Koomagi R, Mattern J (1999). PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. Anticancer Res, 19, 651-5.
  23. Wojcik E, Jakubowicz J, Skotnicki P, et al (2010). IL-6 and VEGF in small cell lung cancer patients. Anticancer Res, 30, 1773-8.

Cited by

  1. Albumin-globulin Ratio for Prediction of Long-term Mortality in Lung Adenocarcinoma Patients vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6449
  2. Serum Vascular Endothelial Growth Factor-A (VEGF-A) as a Biomarker in Squamous Cell Carcinoma of Head and Neck Patients Undergoing Chemoradiotherapy vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3261
  3. Oral Glutamine Supplementation Reduces Radiotherapy-induced Esophagitis in Lung Cancer Patients vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.53
  4. Is there any Potential Clinical Impact of Serum Phosphorus and Magnesium in Patients with Lung Cancer at First Diagnosis? A Multi-institutional Study vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.77
  5. IL-6 polymorphism in non-small cell lung cancer: a prognostic value? vol.36, pp.5, 2015, https://doi.org/10.1007/s13277-014-3006-6
  6. Differential diagnosis of lung cancer, its metastasis and chronic obstructive pulmonary disease based on serum Vegf, Il-8 and MMP-9 vol.6, pp.1, 2016, https://doi.org/10.1038/srep36065